No, Agenus does not pay dividends to its common shareholders. As a clinical-stage biopharmaceutical research enterprise focused on advancing complex immuno-oncology pipelines and experimental cancer therapies, the company operates at a net loss and directs all available capital resources, collaboration revenues, and financing proceeds straight back into active research, laboratory studies, and multi-phase clinical trials rather than distributing cash income yields.